The role of serotonin in antipsychotic drug action

被引：141

作者：

Meltzer H.Y. ^{[1
]}

机构：

[1] Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN

来源：

Neuropsychopharmacology | 1999年 / 21卷 / Suppl 1期

关键词：

D O I：

10.1016/S0893-133X(99)00046-9

中图分类号：

学科分类号：

摘要：

Recent interest in the role of serotonin (5-HT) in antipsychotic drug action is based mainly upon the fact that antipsychotic drugs such as clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone are potent 5-HT2a receptor antagonists and relatively weaker dopamine D2 antagonists. These agents share in common low extrapyramidal side effects at clinically effective doses and possibly greater efficacy to reduce negative symptoms. As a group, they also have a superior effect on cognitive function and greater ability to treat mood symptoms in both patients with schizophrenia or affective disorders than typical antipsychotic drugs. The atypical antipsychotic agents vary in their affinities for other types of 5-HT as well as dopamine, muscarinic, adrenergic, and histaminic receptors, some, or all of which, may contribute to their differences in efficacy and side effect profile. Of the other 5-HT receptors which these drugs directly, the 5-HT1a and 5-HT2c receptors are the strongest candidates for contributing to their antipsychotic action and low EPS profile. The 5-HT6 and 5-HT7 receptors may also be of some importance. Stimulation of the 5-HT1a receptor appears to produce many of the same effects as antagonism of the 5-HT2a receptor while antagonism of the 5-HT2c receptor appears to diminish some of the actions of 5-HT2a receptor antagonism. Future antipsychotic drug development can include targeting multiple serotonin receptor subtypes. © 1999 American College of Neuropsychopharmacology.

引用

页码：106S / 115S

页数：9

共 82 条

[1] Abi-Dargham A., Lamelle M., Aghajanian G.K., The role of serotonin in the pathophysiology and treatment of schizophrenia, J Neuropsyclinneurosci, 9, pp. 1-17, (1997)
[2] Ahlenius S., Antipsychotic-like properties of the 5-HT<sub>1a</sub> agonist 8-oH-DPAT in the rat, Pharmacoltoxicol, 64, pp. 3-5, (1988)
[3] Altman H.J., Stone W.S., Ogren S., Evidence for a possi-ble functional interaction between serotonergic and cho-linergic mechanism in memory retrieval, Behav Neural Biol, 48, pp. 49-62, (1987)
[4] Altar C.A., Wasley A.M., Neale R.F., Stone G.A., Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain, Brain Res Bull, 16, pp. 517-525, (1986)
[5] Arndt J., Skarsfeldt T., Do novel antipsychotics have similar pharmacological characteristics?, A Review of the Evidence.Neuropsychopharmacology, 18, pp. 63-101, (1998)
[6] Arvanitis L.A., Miller B.G., Multiple fixed dose of "Sero-quel" (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo, The Seroquel Trial 13 Study Group.Biolpsychia-Try, 42, pp. 233-246, (1997)
[7] Barbato L., Monge A., Stocchi F., Nordera G., Melperone in the treatment of iatrogenic psychosis in Parkinson's Disease, Clinneuropharmacol, 11, pp. 201-207, (1996)
[8] Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P., Risperidone versus clozapine in treatment resistant chronic schizophrenia: A random-ized double-blind study. The Risperidone Study Group, Am J Psychiatry, 155, pp. 499-504, (1998)
[9] Buhot M.-C., Serotonin receptors in cognitive behav-iors, Curropinneurobiol, 7, pp. 243-254, (1997)
[10] Calabrese J., Kimmel S.E., Woyshiville M., Rapport W.J., Trivedi C.J., Meltzer H.Y., Clozapine in treatment refractory mania, Am J Psychiatry, 153, pp. 759-764, (1996)

← 1 2 3 4 5 6 7 8 9 →